A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
about
Signal transduction inhibitors in treatment of myelodysplastic syndromesPhase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor.Oxidative stress, redox regulation and diseases of cellular differentiation.Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.Attenuation of lung fibrosis in mice with a clinically relevant inhibitor of glutathione-S-transferase π.Role of glutathione in cancer progression and chemoresistance.New G-CSF agonists for neutropenia therapy.Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.Emerging biological therapies for the treatment of myelodysplastic syndromes.A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
P2860
Q26829903-DCC6B523-21E6-428D-AABF-76091631BCB2Q33401001-D8ECCB63-5431-43D5-A28E-70A2AF071333Q35607713-8CE89FC5-A1F1-4A32-9B32-BCD3D17FA217Q35611511-1B6DAFC2-6C1A-4BF7-A7F1-1AC28BF3BA3FQ36125613-654583AB-36B3-4354-97AB-E28A53F53A90Q37041521-08D12C13-EBE6-4E49-9F27-429F74F1564BQ38114436-C60B096B-6375-4B01-AE89-BAC9EC3FFA12Q38145338-23C95627-7DF4-43B9-9B40-80ABF2699022Q38365967-2C361BF9-CFB7-4F02-8722-06F094E3D931Q38834981-7507E4F1-3B11-42E7-8CB3-696275DAF100Q38874826-BA778E0E-1646-4421-B127-958E23395686Q39413114-1C93729B-A0BF-4FAB-A785-82FC344BBFD7Q50280245-D8A1CBCE-F70B-4A96-9379-124B0834DE12
P2860
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A phase 2 randomized multicent ...... risk myelodysplastic syndrome.
@en
A phase 2 randomized multicent ...... risk myelodysplastic syndrome.
@nl
type
label
A phase 2 randomized multicent ...... risk myelodysplastic syndrome.
@en
A phase 2 randomized multicent ...... risk myelodysplastic syndrome.
@nl
prefLabel
A phase 2 randomized multicent ...... risk myelodysplastic syndrome.
@en
A phase 2 randomized multicent ...... risk myelodysplastic syndrome.
@nl
P2093
P2860
P356
P1433
P1476
A phase 2 randomized multicent ...... risk myelodysplastic syndrome.
@en
P2093
Alan F List
Dale Schaar
Daruka Mahadevan
Deborah Mulford
Gail L Brown
John Godwin
Mark Rarick
Mikkael Sekeres
P2860
P304
P356
10.1002/CNCR.26469
P407
P577
2011-09-01T00:00:00Z